<i>In vitro</i> activity of robenidine analogue NCL195 against methicillin-resistant <i>Staphylococcus pseudintermedius</i>
(MRSP) in dogs, poses significant challenges for effective treatment options in veterinary practice. Here, we show that NCL195, a member of a novel class of pyrimidine compounds, exhibits antibacterial activity against 160 MRSP isolates collected from dogs from multiple clinical cases. Additionally, no resistant mutants developed during prolonged serial passage experiments, and NCL195 showed low lysis of dog and sheep red blood cells. Developing NCL195 as an "animal-only" drug promotes the "responsibility" and "refinement" principles of antimicrobial stewardship.
Authors
- Lucy Woolford (ORCID: https://orcid.org/0000-0001-7271-2937)
- Henrietta Venter (ORCID: https://orcid.org/0000-0001-5569-7755)
- Adam McCluskey (ORCID: https://orcid.org/0000-0001-7125-863X)
- Stephen W. Page (ORCID: https://orcid.org/0000-0001-5312-2149)
- Abiodun D. Ogunniyi (ORCID: https://orcid.org/0000-0001-9308-5629)
- Darren J. Trott (ORCID: https://orcid.org/0000-0002-8297-5770)
- Tania Veltman (ORCID: https://orcid.org/0000-0003-1613-7506)
- Mark A T Blaskovich
- Meng Siak
- Tatiana P Soares da Costa
- Sayara Bista
- Kelly A Young
- Hang Thi Nguyen
Institutions
- National Iranian Oil Company (Iran) (IR)
- The University of Queensland (AU)
- University of South Australia (AU)
- Government of Western Australia (AU)
- CNR de la Résistance aux Antibiotiques (FR)
- The University of Adelaide (AU)
- University of Newcastle Australia (AU)
- Newcastle University (GB)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2026-04-30
- DOI
- https://doi.org/10.1128/spectrum.03187-25
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00